Skip to main navigation Skip to search Skip to main content

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

  • Vishnu Prasath
  • , Hinda Boutrid
  • , Robert Wesolowski
  • , Mahmoud Abdel-Rasoul
  • , Cynthia Timmers
  • , Maryam Lustberg
  • , Rachel M. Layman
  • , Erin Macrae
  • , Ewa Mrozek
  • , Charles Shapiro
  • , Kristyn Glover
  • , Mark Vater
  • , G. Thomas Budd
  • , Lyndsay Harris
  • , Claudine Isaacs
  • , Claire Dees
  • , Charles M. Perou
  • , Gary L. Johnson
  • , Andrew Poklepovic
  • , Helen Chen
    • Miguel Villalona-Calero, William Carson, Daniel G. Stover, Bhuvaneswari Ramaswamy

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Nursing and Health Professions